The Interface Between Critical Acid-base Mediators and the Renal Bacterial Defense (R01)
- R01 DK 106286 -02 (Andrew L. Schwaderer) 06/15/2015-03/31/2019
- NIH/NIDDK $291,075
Our long-term research goal is to develop new pyelonephritis treatment strategies that reduce antibiotic exposure and preserve renal function in populations at risk. The proposed research will provide the foundation to include modulation of acid-base mediators in pyelonephritis management, thereby expanding treatment scope beyond antibiotics.
Role of Urothelium in Epithelial Integrity and Innate Defense of the Kidney
- K08 DK 102594 (Michael “Brian” Becknell) 06/2015 – 05/31/2020
- NIH-NIDDK $661,430.00
Novel Mouse Models to Assess the in vivo Significance of Ribonuclease 7 in Urinary Tract Defense (R03)
- R03 DK 109242 (John D Spencer) 04/01/2016 – 03/31/2018
- NIH-NIDDK $106,378.00
The goal of this proposal is to develop novel transgenic mouse models to investigate the impact of RNase 7 overexpression on the developing urinary tract in vivo.
Nuclear Receptor and MAP Kinase Signaling in Podocyte Injury (R01)
- R01 DK095059-01-A1 (William E. Smoyer) 07/1/2013 - 08/24/2018
- NIH-NIDDK $218,941
The goal of this project is to define specific molecular signaling pathways able to regulate podocyte injury in NS to develop more targeted and less toxic therapies for NS. The objective is to determine the ability of the glucocorticoid receptor (GR), peroxisome proliferator-activated receptor g (PPARg), and MAPK signaling pathways to regulate podocyte injury, and to exploit this knowledge to develop more effective novel therapies for NS.
Integrative Proteomics & Metabolomics for Pediatric Glomerular Disease Biomarkers
- UM1 DK 100866-01 (William E. Smoyer) 9/16/2013-3/24/2017
- NIH-NIDDK $394,163
The overall objective of this proposal is to successfully recruit 600 children with four glomerular diseases (Minimal Change Nephrotic Syndrome [MCNS], Focal Segmental Glomerulosclerosis [FSGS], IgA Nephropathy [IgAN], and Idiopathic Membranous Nephropathy [IMN]) into a three-year longitudinal cohort study that will include integrated proteomic and metabolic analyses of highly phenotyped biological samples to identify predictive biomarkers for pediatric glomerular disease.
Ribonuclease7: Antimicrobial Activity in the Human Kidney and Urinary Tract
- K08 DK094970-02 (John David Spencer) 08/01/2012 – 08/31/2017
- NIH-NIDDK $676,851.00
The goal of this proposal is to study the structure, function, and biological relevance of ribonuclease 7, a novel AMP that has potent antimicrobial properties in the human urinary tract.